Medscape NEW YORK, NY (updated) — Using bivalirudin (Angiomax, the Medicines Company) instead of heparin monotherapy halved the risk of bleeding among US patients undergoing PCI for stable ischemic heart disease (IHD) or non-ST-elevation ACS ...
TCTMD The original study found no difference in 30-day rates of all-cause death or MI (primary efficacy endpoint) between patients randomized to enoxaparin or unfractionated heparin but did find an increase in TIMI major bleeding with enoxaparin. The ...
EIN News (press release) The Alere INRatio2 PT/INR Professional Monitoring System is not intended to be used for screening purposes and is not intended for use in patients who are transitioning from heparin treatment to warfarin therapy. About Alere By developing new ... and more »
